In conclusion, our findings for the first time demonstrate that two inflammatory biomarkers, MDC and BLC, were independently associated with the significant risk of early stage lung adenocarcinoma, and this significant association persisted even in non-smokers and in stage IA patients. Here, CXCL13 is linked to lung adenocarcinoma.